Pietro Fratta
Affiliations: | Neuromuscular Diseaes | University College London, London, United Kingdom |
Google:
"Pietro Fratta"Mean distance: (not calculated yet)
BETA: Related publications
See more...
Publications
|
You can help our author matching system! If you notice any publications incorrectly attributed to this author, please sign in and mark matches as correct or incorrect. |
| Dargan R, Mikheenko A, Johnson NL, et al. (2024) Altered mRNA transport and local translation in iNeurons with RNA binding protein knockdown. Biorxiv : the Preprint Server For Biology |
| Wilkins OG, Chien MZYJ, Wlaschin JJ, et al. (2024) Creation of de novo cryptic splicing for ALS and FTD precision medicine. Science (New York, N.Y.). 386: 61-69 |
| Brown AL, Wilkins OG, Keuss MJ, et al. (2024) Author Correction: TDP-43 loss and ALS-risk SNPs drive mis-splicing and depletion of UNC13A. Nature |
| Spence H, Waldron FM, Saleeb RS, et al. (2024) RNA aptamer reveals nuclear TDP-43 pathology is an early aggregation event that coincides with STMN-2 cryptic splicing and precedes clinical manifestation in ALS. Acta Neuropathologica. 147: 50 |
| Milioto C, Carcolé M, Giblin A, et al. (2024) PolyGR and polyPR knock-in mice reveal a conserved neuroprotective extracellular matrix signature in C9orf72 ALS/FTD neurons. Nature Neuroscience |
| Bryce-Smith S, Brown AL, Mehta PR, et al. (2024) TDP-43 loss induces extensive cryptic polyadenylation in ALS/FTD. Biorxiv : the Preprint Server For Biology |
| Seddighi S, Qi YA, Brown AL, et al. (2024) Mis-spliced transcripts generate de novo proteins in TDP-43-related ALS/FTD. Science Translational Medicine. eadg7162 |
| Wilkins OG, Chien MZYJ, Wlaschin JJ, et al. (2023) Creation of de novo cryptic splicing for ALS/FTD precision medicine. Biorxiv : the Preprint Server For Biology |
| Fisher EMC, Greensmith L, Malaspina A, et al. (2023) Opinion: more mouse models and more translation needed for ALS. Molecular Neurodegeneration. 18: 30 |
| Mehta PR, Brown AL, Ward ME, et al. (2023) The era of cryptic exons: implications for ALS-FTD. Molecular Neurodegeneration. 18: 16 |